Results 171 to 180 of about 7,748 (215)
Some of the next articles are maybe not open access.

CLL immunotoxins

Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire   +2 more sources

Recombinant immunotoxins

Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan   +3 more
openaire   +2 more sources

Immunotoxins

Expert Opinion on Pharmacotherapy, 2000
Immunotoxins are molecules which contain a protein toxin connected to a targeting antibody. The goal of therapy is for the molecule to bind selectively to cancer cells, or to cells mediating autoimmune disease, internalise and then for the toxin to kill the cell.
openaire   +2 more sources

Immunotoxin Therapy

Neurosurgery Clinics of North America, 1996
Immunotoxins are extremely potent agents that recognize specific antigens located on metastatic tumor cells and cause cytotoxicity after cell entry by inhibiting protein synthesis. These agents have considerable in vitro efficacy against numerous metastatic tumor cell lines.
openaire   +2 more sources

Immunotoxins

Annual Review of Immunology, 1985
E S, Vitetta, J W, Uhr
  +5 more sources

Immunotoxins

1997
Abstract Immunotoxins (ITs) are cell type-specific cytotoxic agents consisting of an antibody linked to a protein toxin. The antibody component is responsible for directing the toxin selectively to the target cell and the toxin component is responsible for killing the cell (for reviews on ITs see refs 1—5).
Elaine J Derbyshire   +2 more
openaire   +1 more source

Immunotoxins: the power and the glory

Immunology Today, 1992
Immunotoxins are hybrid proteins in which the potent cytocidal action of a toxin is harnessed for the selective destruction of target cells by attachment to a specific monoclonal antibody (mAb) or growth factor. This brief article describes the latest advances in the molecular and cellular biology, pharmacology and clinical evaluation of immunotoxins ...
E J, Wawrzynczak, E J, Derbyshire
openaire   +2 more sources

Chemical Construction of Immunotoxins

Molecular Biotechnology, 2001
Immunotoxins (ITs) are chimeric proteins consisting of an antibody linked to a toxin. The antibody confers specificity (ability to recognize and react with the target), whereas the toxin confers cytotoxicity (ability to kill the target) (1-3). ITs have been used in both mice and humans to eliminate tumor cells, autoimmune cells, and virus-infected ...
V, Ghetie, E S, Vitetta
openaire   +3 more sources

[Immunotoxins].

Bulletin du cancer, 1983
Immunotoxins are conjugates between antibodies especially directed against cancer cells and a subunit of a powerful toxin. We used the A-chain of ricin. These conjugates are specifically cytotoxic when used at very low concentrations in vitro and can destroy more than 99.99% of clonogenic cells.
F K, Jansen   +13 more
openaire   +1 more source

Immunotoxins and Recombinant Immunotoxins in Cancer Therapy

2006
Targeted cancer therapy in general and immunotherapy in particular, combines rational drug design with the progress in understanding cancer biology. This approach takes advantage of our recent knowledge of the mechanisms by which normal cells are transformed into cancer cells, thus, using the special properties of cancer cells to device novel ...
Yoram Reiter, Avital Lev
openaire   +1 more source

Home - About - Disclaimer - Privacy